TABLE 1.
Evaluation of target coverage for 15 lung SBRT patients for both plans. Prescription was 50 Gy in five fractions.
| Target volume | Parameters | Truebeam VMAT | Halcyon VMAT | P‐value |
|---|---|---|---|---|
| PTV | PTVD99 (Gy) | 49.1 ± 1.9 (47.8–56.2) | 48.7 ± 1.5 (47.7–54.1) | 0.04 |
| CI | 1.00 ± 0.03 (0.97–1.07) | 1.01 ± 0.03 (0.98–1.09) | n. s. | |
| HI | 1.23 ± 0.04 (1.2–1.4) | 1.24 ± 0.03 (1.2–1.3) | n. s. | |
| GI | 4.34 ± 0.9 (3.40–7.07) | 4.64 ± 1.1 (3.5–7.6) | 0.004 | |
| D2cm (%) | 51.7 ± 4.5 (44.6–61.6) | 52.1 ± 5.5 (44.9–62.3) | n. s. | |
| GD (cm) | 1.16 ± 0.23 (0.83–1.62) | 1.23 ± 0.25 (0.85–1.71) | 0.001 | |
| ITV | Dmin (Gy) | 53.4 ± 2.3 (49.4–56.9) | 53.4 ± 2.5 (48.9–58.2) | n. s. |
| Dmax (Gy) | 61.5 ± 2.5 (57.7–68.3) | 62.2 ± 1.7 (59.0–65.7) | n. s. | |
| Dmean (Gy) | 58.1 ± 1.9 (55.4–63.1) | 58.6 ± 1.71 (55.5–61.8) | n. s. |
Mean ± SD (range) was reported. n. s., not statistically significant.